Axsome Therapeutics (AXSM) Raw Materials (2022 - 2026)

Axsome Therapeutics has reported Raw Materials for 5 years, with the latest figure at $11.9 million in Q1 2026.

• Quarterly Raw Materials rose 2.81% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (up 2.81% YoY) and the FY2025 annual result came in at $10.4 million, up 8.76% from the prior year.
• Raw Materials advanced to $11.9 million in Q1 2026 per AXSM's latest filing, from $10.4 million in the prior quarter.
• Over five years, Raw Materials peaked at $12.4 million in Q3 2025 and troughed at $2.1 million in Q3 2022.
• A 5-year average of $7.4 million and a median of $7.7 million in 2024 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2023 and 2026: Raw Materials surged 123.78% in 2023, then rose 2.81% in 2026.
• Over 5 years, Raw Materials stood at $2.5 million in 2022, then surged by 123.78% to $5.5 million in 2023, then soared by 72.41% to $9.5 million in 2024, then climbed by 8.76% to $10.4 million in 2025, then gained by 14.26% to $11.9 million in 2026.
• According to Business Quant data, Raw Materials over the past three periods registered $11.9 million, $10.4 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.